1 Caron KMI, James LR, Kim HS, Morham SG, Sequeira Lopez MLS, Ariel GR, et al. A genetically clamped renin transgene for the induction of hypertension [J]. Proc Natl Acad Sci, 2002;99(12): 8248-5
2 d'Uscio LV, Shaw S, Barton M, Liischer TF. Losartan hut not verapamil inhibits angiotensin II-induced tissue endothelin-1 in-crease role of blood pressure and endothelial function [J]. Hy-pertension, 1998;31(6): 1305-10
3 Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Ef-fect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension [J]. Hypertension, 2000; 35(1): 501-6
4 Brooks DP, OHstein EH, Ruffolo RK. Pharmacology of epro-sartan, an angiotensin II receptor antagonist: exploring hypothe-ses from clinical data[J]. Am Heart J, 1999; 138(3 Pt 2): S246-51
5 Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment [J]. Hypertension, 1998; 31(2): 684-91
6 Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the cande-sartan and lisinopril microalbuminuria (CALM) study[J]. BMJ, 2000; 321(7274): 1440-4
7 Lindholm LH, Ibsen H, Dahl B, Devereux RB, Beevers G, Faire Ud, et al. Cardiovascular morbidity and mortality in pa-tients with diabetes in the losartan intervention for endpoint re-duction in hypertension study (life): a randomised trial against atenolol[J]. The Lancet, 2002; 359(1): 1004-10
8 Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study [J]. J Hum Hypertens, 1998; 12(8): 505-10
9 Azizi M, Guyene IT, Chatellier G, Wargon M, Menard J. Ad-ditive effects of losartan and enalapril on blood pressure and plasma active renin[J]. Hypertension, 1997; 29(2): 634-40
10 Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Ma-zerska M, Battaglia C, et al. Short and long-term effect of an-giotensin II receptor blockade in rats with experimental disease [J]. J Am Soc Nephrol, 1993; 4(1): 40-9
11 Rumuzzi A, Mohamed El. Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease [J]. Exper Nephrol, 1996; 4(Suppl 1): 27-33
12 Plum J, Bunten B, Nemeth R, Grabensee B. Effects of the an-giotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension[J]. J Am Soc Nephrol, 1998; 9(12): 2223-34
13 liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats [J]. Acta Pharmacol Sin, 2003; 24 (1): 67-73
14 竺艳娟,傅辰生,蒋金根,廖履坦,丁小强.Valsartan对自发性高血压大鼠肾脏结构与功能的保护作用[J].中华肾脏病杂志,2000; 16(5): 316-9
15 Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P. The effect of irbesartan on the develop-ment of diabetic nephropathy in patients with type 2 diabetes [J]. N Engl J Med, 2001; 345(12): 870-8
16 Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 cKabetes and ne-phropathy[J]. N Engl J Med, 2001; 345(12): 861-9
17 Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D,Ambrosio R, et al. Irbesartan reduces tlie albumin excretion rate in microalbiuninuric type 2 diabetic patients independently of hypertension[J]. Diabetes Care, 2002; 25(11): 1909-13
18 Chan JC, Critchley JA, Tomlinson B, Chan TY,Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassi-um and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus [J]. Am J Nephrol, 1997; 17(1): 72-80
19 Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE, Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria [J]. J Pediatr, 2003; 143(1): 89-97
20 Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis [J]. Am J Kidney Dis, 2004; 43(2): 260-8
21 Klahr S, Morrissey JJ. Comparative study of ACE inhibitor and angiotensin II receptor antagonists in interstitial scaring [J]-Kidney Int, 1997; 52(S63): Sill-4
22 G6mez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, L6pez-Armada MJ, Plaza JJ, et al. Effects and interactions of endo-thelin-1 and angiotensin ii on matrix protein expression and syn-thesis and mesangial cell growth[J], Hypertension, 1996; 27(4): 885-92
23 Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME. Transform-ing growth factor beta 1 and renal injury following subtotal ne-phrectomy in the rat: role of the renin-angiotensin system [J]. Kidney Int, 1997; 51(5): 1553-67
24 Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatzi-antoniou C. Regression of renal vascular and glomerular fibro-sis: role of angiotensin II receptor antagonism and matrix metal-loproteinases[J]. J Am Soc Nephrol, 2003; 14(5): 1132-44
25 张艳玲,段惠军,李英,刘芳,史永红,李英敏,等.洛沙坦对糖尿病大鼠肾脏细胞凋亡及FAS和FAS-L表达的影响[J].中华肾脏病杂志,2001; 17(5): 331-4
26 Agarwal R. Proinflammatory effects of oxidative stress in chron-ic kidney disease: role of additional angiotensin II blockade [J]. Am J Physiol Renal Physiol, 2003; 284(4): F863-9 |
